What Artelo Biosciences does

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three drug candidates that modulate lipid-signaling pathways, founded in 2017 and headquartered in Solana Beach, California, with a wholly-owned UK subsidiary in Alderley Park. The company targets serious conditions with limited or no approved treatments: ART27.13 is a peripherally restricted synthetic dual CB1/CB2 cannabinoid receptor agonist in Phase 1/2 development for cancer anorexia-cachexia syndrome (CAReS trial across 18 sites in 5 countries), with additional investigator-sponsored programs in glaucoma and a provisional patent for GLP-1 muscle preservation; ART26.12 is the first selective Fatty Acid Binding Protein 5 (FABP5) inhibitor to enter human trials, being developed as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy and other neuropathic and inflammatory conditions; and ART12.11 is a proprietary CBD:tetramethylpyrazine cocrystal with composition-of-matter protection through December 2038, in preclinical development for anxiety and depression.

The business model is pre-revenue: Artelo has no commercial products, no FDA approvals, and no recurring revenue streams, with FY2025 net loss of $12.9 million and only $0.6 million in cash and investments at year-end. Capital is raised through dilutive equity instruments — five public offerings and private placements between June 2025 and May 2026 totaling approximately $32 million plus warrant potential, a $25 million equity access facility, and an unusual Solana cryptocurrency treasury strategy — rather than through product sales. Go-to-market is structured around investigator-sponsored studies and clinical-trial supply rather than commercial sales infrastructure, with the company employing only seven full-time staff. Management indicates ongoing unsolicited partnership discussions with global pharmaceutical companies, suggesting the eventual commercial pathway will likely involve out-licensing or co-development rather than independent launch.

Customer-facing activity is restricted to clinical trial operations across academic medical centers (Queen's University Belfast, Belfast HSC Trust) and a research collaboration with the AI firm ScienceMachine. Marketing and communications are concentrated in investor relations, peer-reviewed scientific publications, and conference presentations rather than physician or patient promotion, consistent with a pre-commercial clinical-stage organization.

Name

Artelo Biosciences

Legal name

Artelo Biosciences, Inc.

Website

https://artelobio.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Artelo Biosciences is a clinical-stage biopharmaceutical company developing lipid-signaling therapeutics — including the dual cannabinoid receptor agonist ART27.13, FABP5 inhibitor ART26.12, and CBD cocrystal ART12.11 — for cancer cachexia, neuropathic pain, and CNS disorders, with no approved products and revenue generated solely through dilutive financings.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

Keywords

• Clinical-stage biopharmaceuticals
• Endocannabinoid therapeutics
• Lipid-signaling modulation
• FABP inhibitors
• Cannabinoid receptor agonists

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. No Commercial Revenue: Artelo Biosciences is a clinical-stage biopharmaceutical company with no commercial products. The company currently has no product revenue and is focused on developing its pipeline of drug candidates through clinical trials. All revenue-related activity consists of raising capital through equity financings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of three drug candidates that modulate lipid-signaling pathways and the endocannabinoid system. The pipeline includes ART27.13 (dual CB1/CB2 receptor agonist for cancer anorexia-cachexia syndrome), ART26.12 (selective FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and neuropathic pain), and ART12.11 (CBD:TMP cocrystal for anxiety and depression). The company has no commercial products and currently generates no product revenue.

Product overview

Artelo Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of three distinct drug candidates targeting lipid-signaling pathways. The pipeline consists of: ART27.13 (dual cannabinoid receptor agonist for cancer anorexia-cachexia), ART26.12 (FABP5 inhibitor for neuropathic pain and cancer), and ART12.11 (CBD-based cocrystal for anxiety and depression). The company is currently conducting Phase 1/2 clinical trials for ART27.13 and ART26.12, with ART12.11 in preclinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• ART27.13 ART27.13 is a peripherally restricted, orally administered, synthetic dual cannabinoid receptor (CB1 and CB2) agonist developed as a first-in-class treatment for cancer anorexia-cachexia syndrome (CACS) and explored for muscle preservation in GLP-1 therapy and glaucoma. It is structurally distinct from phytocannabinoids like THC to avoid controlled substance scheduling. Currently in Phase 1/2 clinical trials (CAReS study).
• ART26.12 ART26.12 is a potent and selective Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a peripherally acting, non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN), other neuropathic pain, psoriasis, and certain cancers. Phase 1 results showed all adverse events were mild, transient, and self-resolving.
• ART12.11 ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) designed to improve bioavailability and pharmacokinetics of CBD compared to other forms of CBD in preclinical models. It is being developed for the treatment of anxiety and depression.

Quantifiable outcome

• 64% of patients (14/22) reported weight stabilization or weight gain at day 28 in Phase 1 CAReS trial
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Queen's University BelfastcoreStrategic or Co-development Partner · 25 March 2026Academic partnership for ART27.13 development in glaucoma market expansion, working in conjunction with Glaucoma UK and HSC R&D Division.
• Belfast Health and Social Care TrustcoreStrategic or Co-development Partner · 18 March 2026Investigator-sponsored clinical study evaluating ART27.13 (peripherally selective synthetic cannabinoid) in patients with glaucoma or ocular hypertension. First patient enrollment anticipated in Q2 2026. Artelo will supply ART27.13 capsules as Investigational Medicinal Product.
• Global Pharmaceutical Companies (Unsolicited)minorStrategic or Co-development Partner · 1 January 2026Attracted unsolicited partnership interest from global pharmaceutical companies. Discussions ongoing.
• Queen's University Belfast (CAReS)coreStrategic or Co-development Partner · 5 September 2025Academic medical center partnership for CAReS (Cancer Appetite Recovery Study) Phase 1/2 trial evaluating ART27.13 in cancer anorexia-cachexia syndrome with 18 sites across 5 countries.
• ScienceMachinecoreTechnology or Integration · 1 January 2025Strategic AI partnership to accelerate development of FABP5 inhibitor platform using ScienceMachine's AI agent technology. Since collaboration began in 2025, ScienceMachine has analyzed Artelo's biological datasets, identifying potential proteins indicative of FABP5 target engagement in healthy volunteers and novel protein and lipid signatures correlated with ART26.12's analgesic effect. Preliminary results from psoriasis model study planned for publication later in 2026.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Corbus Pharmaceuticals: Corbus develops cannabinoid receptor-targeting drug candidates for inflammatory and fibrotic diseases, sharing Artelo's strategy of modulating endocannabinoid system pathways for serious conditions with limited treatment options.
• Botanix Pharmaceuticals: Botanix develops CBD-based therapeutics for dermatology indications including psoriasis, overlapping directly with Artelo's ART26.12 psoriasis program and Artelo's CBD-cocrystal technology.
• InMed Pharmaceuticals: InMed is a clinical-stage pharmaceutical company developing cannabinoid-based therapeutics (including rare-disease and dermatology indications), directly comparable to Artelo's CBD:TMP cocrystal (ART12.11) and broader cannabinoid pipeline.
• Zynerba Pharmaceuticals: Zynerba develops transdermal CBD therapies for CNS-related conditions including Fragile X and 22q deletion syndromes; its percutaneous delivery and CBD-focused pipeline is comparable to Artelo's ART12.11 CBD:TMP cocrystal approach for CNS indications.
• Skye Bioscience: Skye Bioscience is developing cannabinoid-derived therapeutics, including a CB1-receptor-targeting candidate for glaucoma, making it the most directly comparable peer to Artelo's ART27.13 in glaucoma and to Artelo's broader cannabinoid receptor agonist platform.

Broad incumbents

• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz (via GW Pharma) pioneered FDA-approved cannabinoid therapeutics (e.g., Epidiolex) and is the broad incumbent against which all small cannabinoid-modulating biopharmas — including Artelo — are benchmarked.

Emerging players

• Cara Therapeutics: Cara's peripherally restricted kappa opioid receptor agonist (difelikefalin/Korsuva) shares Artelo's design principle of peripheral selectivity to limit CNS side effects, making its clinical/commercial playbook highly relevant to ART27.13.
• Tetra Bio-Pharma: Tetra develops cannabinoid-derived therapeutics for pain, oncology supportive care, and inflammatory conditions, overlapping Artelo's ART27.13 (cancer cachexia) and ART26.12 (neuropathic pain) indications.
• Anebulo Pharmaceuticals: Anebulo is an early-stage clinical company developing cannabinoid receptor modulators for intoxication and substance-use disorders, sharing Artelo's science platform around selective cannabinoid receptor targeting.
• Sol-Gel Technologies: Sol-Gel is a dermatology-focused specialty pharmaceutical company developing topical treatments for inflammatory skin diseases including psoriasis, comparable to Artelo's ART26.12 psoriasis development pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ArteloBio
• LinkedInlinkedin.com/company/artelo-biosciences-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artelo Biosciences